Does RIPRETINIB Cause Inappropriate schedule of product administration? 200 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 200 reports of Inappropriate schedule of product administration have been filed in association with RIPRETINIB (QINLOCK). This represents 4.5% of all adverse event reports for RIPRETINIB.
200
Reports of Inappropriate schedule of product administration with RIPRETINIB
4.5%
of all RIPRETINIB reports
10
Deaths
35
Hospitalizations
How Dangerous Is Inappropriate schedule of product administration From RIPRETINIB?
Of the 200 reports, 10 (5.0%) resulted in death, 35 (17.5%) required hospitalization.
Is Inappropriate schedule of product administration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 200 reports have been filed with the FAERS database.
What Other Side Effects Does RIPRETINIB Cause?
Fatigue (582)
Alopecia (517)
Extra dose administered (357)
Death (356)
Underdose (345)
Nausea (292)
Drug ineffective (291)
Disease progression (290)
Hospitalisation (280)
Neoplasm progression (263)
What Other Drugs Cause Inappropriate schedule of product administration?
ADAPALENE (16,473)
DUPILUMAB (14,927)
AVOBENZONE\OCTISALATE\OCTOCRYLENE (12,546)
INSULIN GLARGINE (8,982)
INFLIXIMAB (6,847)
INFLIXIMAB-DYYB (5,977)
SECUKINUMAB (4,817)
DULAGLUTIDE (3,606)
VEDOLIZUMAB (3,259)
SACUBITRIL\VALSARTAN (2,870)
Which RIPRETINIB Alternatives Have Lower Inappropriate schedule of product administration Risk?
RIPRETINIB vs RISANKIZUMAB
RIPRETINIB vs RISANKIZUMAB-RZAA
RIPRETINIB vs RISDIPLAM
RIPRETINIB vs RISEDRONATE
RIPRETINIB vs RISEDRONIC ACID